0001213900-20-002501.txt : 20200310 0001213900-20-002501.hdr.sgml : 20200310 20200204111820 ACCESSION NUMBER: 0001213900-20-002501 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Can-Fite BioPharma Ltd. CENTRAL INDEX KEY: 0001536196 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 10 BAREKET STREET, KIRYAT MATALON STREET 2: P.O. BOX 7537 CITY: PETACH TIKVA STATE: L3 ZIP: 4951778 BUSINESS PHONE: 972 39241114 MAIL ADDRESS: STREET 1: 10 BAREKET STREET, KIRYAT MATALON STREET 2: P.O. BOX 7537 CITY: PETACH TIKVA STATE: L3 ZIP: 4951778 CORRESP 1 filename1.htm

Can-Fite BioPharma Ltd.

10 Bareket Street

Kiryat Matalon, P.O. Box 7537

Petach-Tikva 4951778, Israel

 

February 4, 2020

 

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

 

Re: Can-Fite BioPharma Ltd.
 

Registration Statement on Form F-1

File No. 333-236064

 

VIA EDGAR

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Can-Fite BioPharma Ltd. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-1 (File No. 333-236064) of the Registrant (the “Registration Statement”) be accelerated so that it will be declared effective at 9:00 a.m., Eastern Time, on February 5, 2020 or as soon thereafter as may be practicable.

 

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will& Emery LLP, by calling Gary Emmanuel at (212) 547-5541. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.

   

  Very truly yours,
   
  CAN-FITE BIOPHARMA LTD.
   
  By: /s/ Pnina Fishman, Ph.D.
    Name: Pnina Fishman, Ph.D.
    Title:   Chief Executive Officer

 

cc: Gary Emmanuel (McDermott Will & Emery LLP)